The department of health has issued a fact sheet to prescribers and pharmacists following the listing of the first biosimilar infliximab (Inflectra®). The Q&A style fact sheet explains the difference between Remicade® and its biosimilar Inflectra®, as well as the rationale behind allowing substitution at the pharmacy level (a-flagging). Biosimilars do the same thing as ...
Infliximab fact sheet issued to prescribers
2 Dec 2015